Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

被引:0
作者
Carol Jamieson
Vanina Popova
Ella Daly
Kimberly Cooper
Wayne C. Drevets
Heather M. Rozjabek
Jaskaran Singh
机构
[1] Janssen Research & Development,
[2] LLC,undefined
[3] Janssen Research & Development,undefined
[4] Janssen Scientific Affairs,undefined
[5] LLC,undefined
[6] Janssen Research & Development,undefined
[7] LLC,undefined
[8] Janssen Research & Development,undefined
[9] LLC,undefined
[10] Janssen Research & Development,undefined
[11] LLC,undefined
[12] Present Address: Neurocrine Biosciences,undefined
来源
Health and Quality of Life Outcomes | / 21卷
关键词
European Quality of Life Group; Five Dimension; Five Level (EQ-5D-5L); Esketamine; Health-related quality of life (HRQoL); Major depressive disorder; Sheehan Disability Scale; Treatment-resistant depression;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 196 条
[1]  
Hasin DS(2018)Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States JAMA Psychiat 75 336-346
[2]  
Sarvet AL(2006)Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report Am J Psychiatry 163 1905-1917
[3]  
Meyers JL(2020)Management of treatment-resistant depression: challenges and strategies Neuropsychiatr Dis Treat 16 221-234
[4]  
Saha TD(2019)Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews Can J Psychiatry 64 380-387
[5]  
Ruan WJ(2003)Diagnosis and definition of treatment-resistant depression Biol Psychiatry 53 649-659
[6]  
Stohl M(2018)Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study BMC Psychiatry 18 352-522
[7]  
Rush AJ(2018)Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US Commercial Claims Database J Clin Psychiatry. 79 17m11725-236
[8]  
Trivedi MH(2013)The economic burden of treatment-resistant depression Clin Ther 35 512-189
[9]  
Wisniewski SR(2018)Prospective service use and health care costs of medicaid beneficiaries with treatment-resistant depression J Manag Care Spec Pharm 24 226-8
[10]  
Nierenberg AA(1999)Quality of life in depression: daily life determinants and variability Psychiatry Res 88 173-17